Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Clicks: 203
ID: 117531
2020
On the basis of pharmacovigilance data collected over 4 years, the safety profile of nintedanib in patients with IPF was consistent with that observed in clinical trials and described in the product label, with no new safety concerns observed.
Reference Key
ja2020advancessafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lasky JA;Criner GJ;Lazarus HM;Kohlbrenner V;Bender S;Richeldi L;;
Journal Advances in therapy
Year 2020
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32767182
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32767182 doi:10.1007/s12325-020-01452-5 joseph a lasky gerard j criner luca richeldi

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.